Immix Biopharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Immix Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $20.27. The average 1-year stock price forecast is 84.78% higher than the current stock price, while the lowest is $13.2 (+20.33%) and the highest is $27 (+146.13%).

Price Target: $20.27 (+84.78%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$13.2	$20.27	$20	$27
Change	+20.33%	+84.78%	+82.32%	+146.13%

Analyst Ratings

The average analyst rating for Immix Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	2	2	2	4	4	4
Buy	2	2	2	2	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	6	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 14, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $15	Buy	Reiterates	$15	+36.74%	Aug 12, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Reiterates $20 → $19	Buy	Reiterates	$20 → $19	+73.20%	Aug 11, 2026
Gil Blum Needham	Needham	Buy Maintains $21	Buy	Maintains	$21	+91.43%	Aug 10, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $20 → $25	Buy	Reiterates	$20 → $25	+127.89%	Aug 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

15.16M

EPS This Year

-0.74

from -0.89

EPS Next Year

-0.90

from -0.74

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-1.35M	-8.22M	-16.14M	-22.67M	-29.96M	-50.01M
Net Income	-24.38M	-8.23M	-15.43M	-21.61M	-29.44M	-46.88M
EPS	-	-	-	-	-0.89	-0.74
Free Cash Flow	-2.10M	-4.31M	-5.94M	-7.55M	-13.61M	-38.40M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.51
Avg	-0.74
Low	-1.00

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-